Odronextamab bla for treatment of relapsed/refractory follicular lymphoma (fl) and diffuse large b-cell lymphoma (dlbcl) accepted for fda priority review

If approved, odronextamab would be the first and only bispecific antibody approved in both fl and dlbcl – the two most common subtypes of non-hodgkin lymphoma

REGN Ratings Summary

REGN Quant Ranking